



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

6th August, 2026

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received a Final Order from the ACIT Cir 7(1)(1) with the Demand Liability of Rs 23.21 Crores. The relevant details to be disclosed are as under:

Sr no	Particulars	Details
1	Name of the authority	OGE to CIT-Appeal received for the GSK AY: 1984-85 on 27 th Jan, 2026 and the refund received in Bank on 6 th Aug, 2026 for Rs 52.00 Cr
2	Nature and details of the action(s) taken, initiated or order(s) passed	The said Refund is received post the OGE to CIT-Appeal for the GSK assessment for the AY: 84-85.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	OGE to CIT-Appeal received dated on 27 th Jan, 2026 and the actual refund received today i.e. 6 th Aug, 2026.
4	Details of violation(s) / contravention(s) committed or alleged to be committed	N.A.
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Interest Income of Rs 42.09 Cr on GSK Refund for AY: 84-85 will be credited to P/L account as Income.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni

Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151